Weight Loss Injections Posted or Updated on 30 Jun 2025

23 June 2025: From 23 June 2025 following approval by NICE, tirzepatide (Mounjaro®) will be available in the NHS for eligible patients who meet the strict, nationally-set, criteria. 

The current criteria is that patients are those with a BMI of 40 or higher, and with four or more of the qualifying comorbidities (hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease and type 2 diabetes) will be eligible for assessment to identify their suitability for Mounjaro. Anyone not meeting these criteria will not be eligible for assessment in the first year of the drug being available. 

Please do not contact your GP; if you are eligible to be assessed you will be contacted over the coming months and invited to attend an appointment for assessment. Those with the greatest clinical need will be contacted first.

For more information about alternative local weight management services, visit the ICS website - Local Weight Management services - Staffordshire and Stoke-on-Trent, ICS.